William Blair Predicts FibroGen’s Q1 Earnings (NASDAQ:FGEN)

FibroGen, Inc. (NASDAQ:FGEN) – Investment analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of FibroGen in a note issued to investors on Tuesday, April 1st. William Blair analyst A. Hsieh expects that the biopharmaceutical company will earn ($0.21) per share for the quarter. William Blair has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. William Blair also issued estimates for FibroGen’s Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.22) EPS.

A number of other analysts also recently commented on the stock. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of FibroGen in a research report on Tuesday, March 18th. StockNews.com initiated coverage on FibroGen in a research report on Sunday. They issued a “hold” rating for the company.

FibroGen Stock Up 2.0 %

FGEN stock opened at $0.31 on Thursday. The company has a 50-day simple moving average of $0.45 and a 200 day simple moving average of $0.43. The company has a market capitalization of $30.90 million, a P/E ratio of -0.25 and a beta of 0.82. FibroGen has a fifty-two week low of $0.18 and a fifty-two week high of $2.15.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $3.14 million during the quarter, compared to the consensus estimate of $24.91 million.

Institutional Investors Weigh In On FibroGen

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 32,884 shares during the period. Two Sigma Securities LLC purchased a new position in FibroGen in the 4th quarter worth about $27,000. FMR LLC raised its holdings in FibroGen by 21.8% during the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 68,569 shares during the period. XTX Topco Ltd lifted its stake in FibroGen by 423.8% during the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 77,693 shares in the last quarter. Finally, Velan Capital Investment Management LP acquired a new position in shares of FibroGen in the fourth quarter worth about $42,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

Insider Buying and Selling

In other FibroGen news, Director James A. Schoeneck bought 250,000 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The stock was acquired at an average cost of $0.35 per share, with a total value of $87,500.00. Following the completion of the purchase, the director now directly owns 323,722 shares in the company, valued at approximately $113,302.70. This trade represents a 339.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thane Wettig purchased 145,000 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was acquired at an average price of $0.35 per share, for a total transaction of $50,750.00. Following the transaction, the chief executive officer now owns 543,329 shares of the company’s stock, valued at $190,165.15. The trade was a 36.40 % increase in their position. The disclosure for this purchase can be found here. 1.98% of the stock is owned by corporate insiders.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.